NASDAQ:BLTE Belite Bio (BLTE) Stock Price, News & Analysis $163.05 0.00 (0.00%) Closing price 08/7/2026 04:00 PM EasternExtended Trading$162.66 -0.39 (-0.24%) As of 08/7/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Belite Bio Stock (NASDAQ:BLTE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Belite Bio alerts:Sign Up Key Stats Today's Range$161.67▼$164.3050-Day Range$134.93▼$163.0552-Week Range$60.00▼$200.00Volume126,434 shsAverage Volume158,184 shsMarket Capitalization$6.54 billionP/E RatioN/ADividend YieldN/APrice Target$203.00Consensus RatingModerate Buy Company Overview Belite Bio, Inc. (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation. Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages. The company has established research collaborations with academic institutions and contract research organizations to advance its lead programs through regulatory milestones, emphasizing optimization of safety, efficacy and pharmacokinetic profiles to support future clinical trials. Based in the United States, Belite Bio is led by a management team with extensive experience in biotechnology, drug development and regulatory affairs. The company’s strategic vision is to deliver innovative therapies for metabolic disorders with significant unmet medical needs and to pursue global clinical development to reach diverse patient populations. AI Generated. May Contain Errors. Read More Belite Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreBLTE MarketRank™: Belite Bio scored higher than 72% of companies evaluated by MarketBeat, and ranked 192nd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBelite Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialBelite Bio has a consensus price target of $203.00, representing about 24.5% upside from its current price of $163.05.Amount of Analyst CoverageBelite Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Belite Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Belite Bio are expected to grow in the coming year, from ($3.17) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Belite Bio is -64.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Belite Bio is -64.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBelite Bio has a P/B Ratio of 7.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Belite Bio's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.78% of the float of Belite Bio has been sold short.Short Interest Ratio / Days to CoverBelite Bio has a short interest ratio ("days to cover") of 7.06.Change versus previous monthShort interest in Belite Bio has recently increased by 0.07%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBelite Bio does not currently pay a dividend.Dividend GrowthBelite Bio does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.89 News SentimentBelite Bio has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Belite Bio this week, compared to 5 articles on an average week.Search Interest3 people have searched for BLTE on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Belite Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,858,100.00 in company stock.Percentage Held by Insiders13.29% of the stock of Belite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions0.53% of the stock of Belite Bio is held by institutions.Read more about Belite Bio's insider trading history. Receive BLTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BLTE Stock News HeadlinesBelite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Consensus Rating of "Moderate Buy" from BrokeragesAugust 9 at 2:14 AM | americanbankingnews.comBelite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial ResultsAugust 7 at 1:45 AM | markets.businessinsider.comBarricks gold output fell from 2 million ounces to 719000Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-largest miner running on fumes. Newmont's $15 billion purchase of Newcrest, the largest mining deal in history, still couldn't keep output growing, proof that majors must keep buying to survive. With record cash flows and shrinking mines, gold majors are positioned to launch a wave of acquisitions targeting the best junior assets. | Golden Portfolio (Ad)Belite Bio: The Oral Route Is The Real Competitive MoatJuly 29, 2026 | seekingalpha.comBelite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt ...July 20, 2026 | markets.businessinsider.comBelite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1July 20, 2026 | globenewswire.comBelite Bio Corporate Event Calendar | NASDAQ:BLTEJuly 16, 2026 | benzinga.comBelite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual ConferenceJuly 15, 2026 | globenewswire.comSee More Headlines BLTE Stock Analysis - Frequently Asked Questions How have BLTE shares performed this year? Belite Bio's stock was trading at $159.96 at the start of the year. Since then, BLTE shares have increased by 1.9% and is now trading at $163.05. How were Belite Bio's earnings last quarter? Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) posted its quarterly earnings results on Friday, May, 15th. The company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.60) by $0.26. Read the conference call transcript. When did Belite Bio IPO? Belite Bio (BLTE) raised $36 million in an initial public offering (IPO) on Friday, April 22nd 2022. The company issued 6,000,000 shares at a price of $5.50-$6.50 per share. How do I buy shares of Belite Bio? Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Belite Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Belite Bio investors own include Paycom Software (PAYC), Centrus Energy (LEU), Planet Labs PBC (PL), uniQure (QURE), Vale (VALE). Company Calendar Last Earnings5/15/2026Today8/09/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 BLTE's financial health is in the Green zone, according to TradeSmith. BLTE has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:BLTE CIK1889109 Webbelitebio.com Phone858-246-6240FaxN/AEmployees10Year Founded2018Price Target and Rating Average Price Target for Belite Bio$203.00 High Price Target$266.00 Low Price Target$132.00 Potential Upside/Downside+24.5%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($2.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$77.61 million Net MarginsN/A Pretax MarginN/A Return on Equity-13.14% Return on Assets-12.88% Debt Debt-to-Equity RatioN/A Current Ratio33.71 Quick Ratio33.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$20.54 per share Price / Book7.94Miscellaneous Outstanding Shares40,080,000Free Float34,758,000Market Cap$6.54 billion OptionableNot Optionable Beta-1.22 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:BLTE) was last updated on 8/10/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump's Next Move Could Shrink Your DollarThere's a plan in Washington being called the 'Mar-a-Lago Accord' - a deliberate strategy to weaken the U.S. d...Priority Gold | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredI’ll Keep This Short… (Huge AI Opportunity)Analyst Ross Givens says the top AI opportunity right now isn't Microsoft, Google, Amazon, Apple, or Nvidia - ...Traders Agency | SponsoredAI Bubble Could Finally Be Done - Wall St's WarningWall Street analysts are warning that the AI-driven market rally may be nearing its limits, with some cautioni...TradeSmith | SponsoredChina is not hedging. It's escaping.China's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Belite Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
